

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-45 (canceled).

Claim 46 (currently amended): An element comprising:
a support having a face;
the face having at least two pores spaced from one another to define a node spacing; and
a non-hydrolyzed fibrin network substantially free of unbound fibrinogen covering a portion of the face.

Claim 47 (previously presented): The element according to claim 46 wherein the support is substantially hydrophobic.

Claim 48 (previously presented): The element according to claim 46 wherein the face has a thickness from about 0.1 mm to about 5 mm.

Claim 49 (previously presented): The element according to claim 46 wherein the fibrin network is positioned over a portion of the pores.

Claim 50 (previously presented): The element of claim 46 wherein the pores extend through the thickness of the support.

Claim 51 (previously presented): The element according to claim 46 wherein the node spacing is from about 5 μ m to about 100 μ m.

Claim 52 (previously presented): The element of claim 46 wherein the fibrin network is substantially uniform and homogeneous.

Claim 53 (previously presented): The element according to claim 52 wherein the fibrin network contains less than 1% by weight of fibrinogen that has not reacted.

Claim 54 (previously presented): The element according to claim 53 wherein the fibrin network contains less than 0.5% by weight of fibrinogen that has not reacted.

Claim 55 (previously presented): The element according to claim 54 wherein the fibrin network contains less than 0.1% by weight of fibrinogen that has not reacted.

Claim 56 (previously presented): The element according to claim 55 wherein the fibrin network extends through the pores to a depth of the support of at least 2 μ m.

Claim 57 (previously presented): The element according to claim 56 wherein the node spacing is substantially homogeneous and uniform.

Claim 58 (previously presented): The element according to claim 46 wherein the fibrinogen extends through the thickness of the fibrin network to a depth of at least 10 μ m.

Claim 59 (previously presented): The element according to claim 58 wherein the fibrinogen extends through the thickness of the fibrin network to a depth of at least 20 μ m.

Claim 60 (previously presented): The element according to claim 46 wherein the fibrin network further includes a first face and a second face.

Claim 61 (previously presented): The element according to claim 60 wherein first face is in contact with the support.

Claim 62 (previously presented): The element according to claim 61 wherein second face is stabilized by at least partial cross-linking to form a network of adjacent alveoli.

Claim 63 (previously presented): The element according to claim 60 wherein the fibrin network is provided with cells.

Claim 64 (previously presented): The element according to claim 63 wherein the cells mediate cell-fibrin bonds.

Claim 65 (previously presented): The element according to claim 60 wherein the fibrin network is provided with proteins.

Claim 66 (previously presented): The element according to claim 65 wherein the proteins mediate cell-fibrin bonds.

Claim 67 (previously presented): The element according to claim 62 wherein the at least partially cross-linked fibrin network is 0.5 to 100 μm thick when measured in the dry state.

Claim 68 (previously presented): The element according to claim 67 wherein the at least partially cross-linked fibrin network is 2.5 to 50 μm thick when measured in the dry state.

Claim 69 (previously presented): The element according to claim 62 wherein the alveoli are formed between the cross-linked fibrin.

Claim 70 (previously presented): The element according to claim 69 wherein the alveoli have a volume from about 5 μm^3 to about 25 μm^3 .

Claim 71 (previously presented): The element according to claim 70 wherein the alveoli have an average thickness from about 1 μm to about 5 μm when measured in the dry state.

Claim 72 (previously presented): The element according to claim 46 wherein the pores further include inner faces.

Claim 73 (previously presented): The element according to claim 72 wherein the inner faces are at least partially covered by a water-soluble or substantially water-soluble protein.

Claim 74 (previously presented): The element according to claim 46 wherein the fibrin network is at least partially covered by a water-soluble or substantially water-soluble protein.

Claim 75 (previously presented): The element according to claim 72 wherein the pores are covered by a water-soluble or miscible polar organic additive.

Claim 76 (previously presented): The element according to claim 62 wherein the cross-linked fibrin is at least partially covered by a water-soluble or miscible polar additive.

Claim 77 (previously presented): The element according to claim 76 wherein the water-soluble or miscible polar additive is selected in the group comprising glycerol, sugars and mixtures thereof.

Claim 78 (previously presented): The element according to claim 46 wherein the fibrin network has a moisture content of less than 0.5%.

Claim 79 (previously presented): The element according to claim 46 wherein the fibrin network contains fibronectin.

Claim 80 (previously presented): The element according to claim 79 wherein the fibronectin content is from about 0.5% to about 15%.

Claim 81 (previously presented): The element according to claim 46 wherein the fibrin network contains calcium.

Claim 82 (previously presented): The element according to claim 81 wherein the calcium content is from about 1 μg to about 100 μg per cm^3 of the fibrin network volume.

Claim 83 (previously presented): The element according to claim 81 wherein the calcium is calcium chloride.

Claim 84 (previously presented): The element according to claim 46 wherein the support further includes a second fibrin network superimposed on a first fibrin network.

Claim 85 (previously presented): The element according to claim 84 wherein the first fibrin network is in contact with the support.

Claim 86 (previously presented): The element according to claim 85 wherein the first fibrin network contains alveoli.

Claim 87 (previously presented): The element according to claim 84 wherein the second fibrin network contains alveoli.

Claim 88 (previously presented): The element according to claim 84 wherein the alveoli of the first fibrin network have larger volumes than the alveoli of the second fibrin network.

Claim 89 (previously presented): The element according to claim 46 wherein the support is biocompatible and/or biodegradable.

Claim 90 (withdrawn): A method for producing an element, the method comprising placing a first porous portion of a support in contact with an aqueous solution and submitting a second porous portion of the support to a substantially uniform and homogenous suction force.

Claim 91 (withdrawn): The method according to claim 90 wherein the second porous portion is positioned opposite to the first porous portion.

Claim 92 (withdrawn): The method according to claim 90 wherein the aqueous solution contains fibrin.

Claim 93 (withdrawn): The method according to claim 92 wherein the aqueous solution contains fibrinogen.

Claim 94 (withdrawn): The method according to claim 93 wherein the aqueous solution contains water.

Claim 95 (withdrawn): The method according to claim 90 wherein the suction force pulls the water through the first porous portion.

Claim 96 (withdrawn): The method according to claim 95 wherein the suction force deposits a fibrin network on the first porous portion.

Claim 97 (withdrawn): The method according to claim 96 wherein the fibrin network is deposited substantially uniformly and homogeneously.

Claim 98 (withdrawn): The method according to claim 97 wherein the fibrin penetrates the first porous portion.

Claim 99 (withdrawn): The method according to claim 90 wherein the second porous portion is submitted to a pressure of less than about 0.8×10^5 Pa.

Claim 100 (withdrawn): The method according to claim 99 wherein the second porous portion is submitted to a pressure of less than about 0.5×10^5 Pa.

Claim 101 (withdrawn): The method according to claim 90 wherein a pressure difference is created between the first porous portion and the second porous portion.

Claim 102 (withdrawn): The method according to claim 101 wherein a pressure difference is at least 0.3×10^5 Pa.

Claim 103 (withdrawn): The method according to claim 101 wherein the second porous portion is intermittently submitted to a first pressure and a second pressure.

Claim 104 (withdrawn): The method according to claim 103 wherein the first pressure is less than about 0.8×10^5 Pa.

Claim 105 (withdrawn): The method according to claim 103 wherein the second pressure is less than about 0.8×10^5 Pa.

Claim 106 (withdrawn): The method according to claim 103 wherein the first pressure is at least 5% higher than the second pressure.

Claim 107 (withdrawn): The method according to claim 101 wherein the second porous portion is exposed to a temperature from about 0°C to about 100°C.

Claim 108 (withdrawn): The method according to claim 107 wherein the second porous portion is exposed to a temperature from about 15°C to about 60°C.

Claim 109 (withdrawn): The method according to claim 90 wherein the second porous portion is submitted to reverse osmosis.

Claim 110 (withdrawn): The method according to claim 109 wherein the reverse osmosis causes the diffusion of at least the solution water through the first porous portion.

Claim 111 (withdrawn): The method according to claim 90 wherein the solution contains from about 5 to about 20 mg/ml of fibrinogen-containing materials.

Claim 112 (withdrawn): The method according to claim 111 wherein the solution contains from about 0.01 to about 10 units of thrombin per ml.

Claim 113 (withdrawn): The method according to claim 112 wherein the solution contains from about 0.1 to about 10 units of factor XIII per ml.

Claim 114 (withdrawn): The method according to claim 113 wherein the solution contains from about 1 to about 40 millimoles of calcium chloride per ml.

Claim 115 (withdrawn): The method according to claim 114 wherein the solution contains from about 0 % to about 20% by weight of a water-soluble or miscible polar organic additive.

Claim 116 (withdrawn): The method according to claim 115 wherein the solution contains from about 5% to about 10% by weight of a water-soluble or miscible polar organic additive.

Claim 117 (withdrawn): The method according to claim 116 wherein the additive is glycerol.

Claim 118 (withdrawn): The method according to claim 90 further comprising:
a first step wherein the first porous portion is placed in contact with a solution containing fibrin and/or fibrinogen-containing materials;

a second step wherein the second porous portion is submitted to a suction force to diffuse at least the solution water through the thickness of the porous support and homogeneously and uniformly having penetration of fibrin or fibrinogen across the thickness of the porous support;
and

a third step wherein the fibrin and/or fibrinogen network is stabilized by at least partial cross-linking to form a network of adjacent alveoli.

Claim 119 (withdrawn): The method of claim 118 wherein the solution is in motion.

Claim 120 (withdrawn): The method of claim 119 wherein the solution contains a wetting agent.

Claim 121 (withdrawn): The method of claim 118 wherein the fibrin network is submitted to a washing step.

Claim 122 (withdrawn): The method of claim 121 wherein the fibrin network is submitted to a drying step.

Claim 123 (withdrawn): The method of claim 122 wherein the drying step is accomplished at least partially by lyophilization.

Claim 124 (withdrawn): The method of claim 123 wherein the drying step is accomplished at a temperature from about -30°C to about -100°C.

Claim 125 (withdrawn): The method of claim 124 wherein the drying step is accomplished at a temperature from about -40°C to about -70°C.

Claim 126 (withdrawn): The method of claim 118 wherein the fibrin or fibrinogen-containing materials have a controlled concentration.

Claim 127 (withdrawn): The method of claim 126 wherein the concentration ensures a substantially constant water diffusion through the support.

Claim 128 (withdrawn): The method of claim 90 wherein the support is biocompatible and/or biodegradable.

Claim 129 (withdrawn): The method of claim 90 wherein the porous portion is treated with an aqueous solution before contacting the fibrin and/or fibrinogen-containing materials.

Claim 130 (withdrawn): The method of claim 129 wherein the solution contains a wetting agent, a protein or a polar organic additive, or a mixture thereof.

Claim 131 (currently amended): A filter including a membrane element comprising:
a support having a face;
the face having at least two pores spaced from one another to define a node spacing; and
a non-hydrolyzed fibrin network substantially free of unbound fibrinogen covering a portion of the face.

Claim 132 (currently amended): A bioreactor including a membrane element comprising:

- a support having a face;
- the face having at least two pores spaced from one another to define a node spacing; and
- a non-hydrolyzed fibrin network substantially free of unbound fibrinogen covering a portion of the face.

Claim 133 (currently amended): An implant consisting of an element comprising:

- a support having a face;
- the face having at least two pores spaced from one another to define a node spacing; and
- a non-hydrolyzed fibrin network substantially free of unbound fibrinogen covering a portion of the face.

Claim 134 (currently amended): An artificial skin produced from an element comprising:

- a support having a face;
- the face having at least two pores spaced from one another to define a node spacing; and
- a non-hydrolyzed fibrin network substantially free of unbound fibrinogen covering a portion of the face.